文献速递湿疹皮炎与荨麻疹

环孢素与甲氨蝶呤治疗儿童及青少年重度特应性皮炎:TREAT多中心随机对照试验

Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial.
PubMed 文献 · Br J Dermatol · 2023-01-01

TREAT试验在13个英国和爱尔兰中心纳入103例2-16岁重度特应性皮炎患者,随机接受环孢素(4 mg/kg/日)或甲氨蝶呤(0.4 mg/kg/周)治疗36周并随访24周。环孢素12周时疾病严重度改善更明显,但甲氨蝶呤在60周时显示更优的持续控制。两种药物生活质量均改善且不良反应频率相当。

要点

  • 环孢素12周时o-SCORAD改善优于甲氨蝶呤(均差-5.69)。
  • 甲氨蝶呤在60周时显示更优的持续疾病控制(OR 0.33)。
  • 两种药物生活质量均改善且不良反应频率相当。

核心结论

  • 环孢素和甲氨蝶呤对儿童及青少年重度特应性皮炎在36周内均有效,环孢素起效更快,甲氨蝶呤停药后疾病控制更持久。

研究设计与样本

  • 平行组评估者盲法随机对照试验,在13个英国和爱尔兰中心开展,纳入103例2-16岁对强效外用治疗无反应的重度特应性皮炎患者,随机接受环孢素(4 mg/kg/日)或甲氨蝶呤(0.4 mg/kg/周)治疗36周并随访24周。

主要发现

  • 12周时环孢素组o-SCORAD较基线的改善优于甲氨蝶呤组(均差-5.69,97.5% CI -10.81至-0.57,P=0.01)。
  • 12周时环孢素组达到o-SCORAD 50的比例高于甲氨蝶呤组(OR 2.60,95% CI 1.23-5.49,P=0.01)。
  • 60周时甲氨蝶呤组显示更优的持续控制(OR 0.33,95% CI 0.13-0.85,P=0.02),o-SCORAD 75、EASI 50和EASI 75也呈现类似趋势。
  • 停药后患者报告的复发在环孢素组更高(OR 3.22,95% CI 0.42-6.01,P=0.02)。
  • 两种治疗均改善生活质量且停药后维持,filaggrin状态不影响结局,不良事件频率两组相当,环孢素组5例(10%)和甲氨蝶呤组7例(14%)发生严重不良事件。

临床怎么用

  • 对于儿童及青少年重度特应性皮炎,环孢素可考虑用于需要快速控制病情的患者,甲氨蝶呤可考虑用于需要停药后持续控制的患者。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Conventional systemic drugs are used to treat children and young people (CYP) with severe atopic dermatitis (AD) worldwide, but no robust randomized controlled trial (RCT) evidence exists regarding their efficacy and safety in this population. While novel therapies have expanded therapeutic options, their high cost means traditional agents remain important, especially in lower-resource settings. OBJECTIVES: To compare the safety and efficacy of ciclosporin (CyA) with methotrexate (MTX) in CYP with severe AD in the TREatment of severe Atopic Eczema Trial (TREAT) trial. METHODS: We conducted a parallel group assessor-blinded RCT in 13 UK and Irish centres. Eligible participants aged 2-16 years and unresponsive to potent topical treatment were randomized to either oral CyA (4 mg kg-1 daily) or MTX (0.4 mg kg-1 weekly) for 36 weeks and followed-up for 24 weeks. Co-primary outcomes were change from baseline to 12 weeks in Objective Severity Scoring of Atopic Dermatitis (o-SCORAD) and time to first significant flare (relapse) after treatment cessation. Secondary outcomes included change in quality of life (QoL) from baseline to 60 weeks; number of participant-reported flares following treatment cessation; proportion of participants achieving ≥ 50% improvement in Eczema Area and Severity Index (EASI 50) and ≥ 75% improvement in EASI (EASI 75); and stratification of outcomes by filaggrin status. RESULTS: In total, 103 participants were randomized (May 2016-February 2019): 52 to CyA and 51 to MTX. CyA showed greater improvement in disease severity by 12 weeks [mean difference in o-SCORAD -5.69, 97.5% confidence interval (CI) -10.81 to -0.57 (P = 0.01)]. More participants achieved ≥ 50% improvement in o-SCORAD (o-SCORAD 50) at 12 weeks in the CyA arm vs. the MTX arm [odds ratio (OR) 2.60, 95% CI 1.23-5.49; P = 0.01]. By 60 weeks MTX was superior (OR 0.33, 95% CI 0.13-0.85; P = 0.02), a trend also seen for ≥ 75% improvement in o-SCORAD (o-SCORAD 75), EASI 50 and EASI 75. Participant-reported flares post-treatment were higher in the CyA arm (OR 3.22, 95% CI 0.42-6.01; P = 0.02). QoL improved with both treatments and was sustained after treatment cessation. Filaggrin status did not affect outcomes. The frequency of adverse events (AEs) was comparable between both treatments. Five (10%) participants on CyA and seven (14%) on MTX experienced a serious AE. CONCLUSIONS: Both CyA and MTX proved effective in CYP with severe AD over 36 weeks. Participants who received CyA showed a more rapid response to treatment, while MTX induced more sustained disease control after discontinuation.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Flohr C, Rosala-Hallas A, Jones AP, et al. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial. Br J Dermatol. 2023. PMID: 37722926. doi:10.1093/bjd/ljad281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。